This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
D. Ames , H. Kaduszkiewicz , H. van den Bussche , T. Zimmermann , J. Birks and D. Ashby (2008). For debate: is the evidence for the efficacy of cholinesterase inhibitors in the symptomatic treatment of Alzheimer's disease convincing or not? International Psychogeriatrics, 20, 259–292.
J. L. Cummings , E. Schneider , P. N. Tariot and S. M. Graham for the Memantine MEM-MD-02 Study Group (2006). Behavioral effects of memantine in Alzheimer disease patients receiving donepezil therapy. Neurology, 67, 57–63.
H. Feldman (2001). A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology, 57, 613–620.
S. Gauthier , Y. Wirth and H. J. Mobius (2005). Effects of memantine on behavioral symptoms in Alzheimer's disease patients; an analysis of the neuropsychiatric inventory data of two randomized controlled studies. International Journal of Geriatric Psychiatry, 20, 459–464.
S. Gauthier , H. Loft and J. Cummings (2008). Improvement in behavioral symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. International Journal of Geriatric Psychiatry, 23, 537–545.
R. J. Howard (2007). Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine, 357, 1382–1392.
J. S. Vidal (2008). Evaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French National Health Care Database. Neuroepidemiology, 31, 193–200.